There were no significant differences in asthma symptom scores and mean change from baseline in an asthma symptom score between Ventolin HFA 180 mcg and Ventolin HFA 360 mcg.In vitro dose characterization studies were performed to evaluate the delivery of Ventolin HFA via holding chambers with attached masks. Ventolin HFA or placebo HFA was delivered with either an AeroChamber Plus Valved Holding Chamber or an Optichamber Valved Holding Chamber with mask 3 times daily. Early consideration should be given to adding anti-inflammatory agents, e.g., corticosteroids, to the therapeutic regimen.Fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs in patients with asthma. Do not use Ventolin HFA more frequently than recommended. Exposure to temperatures above 120°F may cause bursting. If the patient needs more doses of Ventolin HFA than usual, this may be a marker of destabilization of asthma and requires reevaluation of the patient and treatment regimen, giving special consideration to the possible need for anti-inflammatory treatment, e.g., corticosteroids.The use of beta-adrenergic agonist bronchodilators alone may not be adequate to control asthma in many patients. Efficacy was assessed by serial forced expiratory volume in 1 second (FEVIn a 12-week, randomized, double-blind trial, Ventolin HFA (101 subjects) was compared with CFC 11/12-propelled albuterol (99 subjects) and an HFA-134a placebo inhaler (97 subjects) in adolescent and adult subjects aged 12 to 76 years with mild to moderate asthma. There are, however, clinical considerations in pregnant women with asthma. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.The expected signs and symptoms with overdosage of albuterol are those of excessive beta-adrenergic stimulation and/or occurrence or exaggeration of any of the signs and symptoms of beta-adrenergic stimulation (e.g., seizures, angina, hypertension or hypotension, tachycardia with rates up to 200 beats/min, arrhythmias, nervousness, headache, tremor, muscle cramps, dry mouth, palpitation, nausea, dizziness, fatigue, malaise, insomnia, hyperglycemia, hypokalemia, metabolic acidosis).As with all inhaled sympathomimetic medicines, cardiac arrest and even death may be associated with an overdose of Ventolin HFA Inhalation Aerosol.Treatment consists of discontinuation of Ventolin HFA together with appropriate symptomatic therapy. Adults: The usual adult dosage in the treatment of urinary tract infections is 1 BACTRIM DS (double strength) tablet or 2 BACTRIM tablets every 12 hours for 10 to 14 days. The counter should show through the window in the actuator.Take the cap off the mouthpiece of the plastic actuator. Dosage is based on your medical condition and response to treatment. In structures outside the blood-brain barrier (pineal and pituitary glands), albuterol concentrations were found to be 100 times those in the whole brain.Studies in laboratory animals (minipigs, rodents, and dogs) have demonstrated the occurrence of cardiac arrhythmias and sudden death (with histologic evidence of myocardial necrosis) when beta-agonists and methylxanthines are administered concurrently. Large doses of intravenous albuterol have been reported to aggravate preexisting diabetes mellitus and ketoacidosis.Beta-adrenergic agonist medicines may produce significant hypokalemia in some patients, possibly through intracellular shunting, which has the potential to produce adverse cardiovascular effects Use of Ventolin HFA may be associated with the following:Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice.The safety data described below reflects exposure to Ventolin HFA in 248 subjects treated with Ventolin HFA in 3 placebo-controlled clinical trials of 2 to 12 weeks’ duration.